What's new
Everything that changed here, newest first: research, patents, portfolio works, books, and the site itself.
September 2026
NewResearch & IP
The competitor Eidolon evidence line
Mark every competitor claim as observed, disclosed, reported, or inferred, so analysis built on it cannot quietly promote a guess.
NewResearch & IP
The customer Eidolon and its limits
Enough reflection of an account that anyone can prepare before acting, bounded by confidentiality terms, privacy obligations, and contractual restrictions.
NewResearch & IP
The person and the role are two records
Keep a role specification and a person's Eidolon as separate linked objects so work is not written for an office as though it were a personality.
NewResearch & IP
The title trap
A role name hides the scope, authority, evidence, exceptions, and outcomes that determine whether work can move.
NewResearch & IP
The worker contract
State what a worker may do, what evidence it must use, when a person reviews it, and how it fails safely.
NewResearch & IP
The Zero Neo principle
New business-operations software should be the last resort. Start with the capabilities already owned and move outward only when evidence shows a real gap.
NewResearch & IP
The Zero Neo reference architecture
Systems of record at the bottom, platform capabilities above them, AI orchestration above that, then workflows, then the mixed workforce, with observable outcomes at the top and purchased software entering only from the side.
NewResearch & IP
Therapy orchestration record
Specify the measurements, transitions, timing, decisions, and exceptions in an adaptive treatment sequence.
NewResearch & IP
Transition and Cutover plan
Move from the current operation through shadow work and narrow authority while keeping rollback available.
NewResearch & IP
Treatment readiness index
Test whether a composite readiness measure can improve treatment timing or selection without hiding weak dimensions.
NewResearch & IP
When Zero Neo should fail
The conditions under which specialized software remains the right answer, stated precisely enough to be used in an actual review.
NewResearch & IP
Work Origin and Incentive map
Find whether work serves the outcome or was created by a rule, incentive, boundary, or information failure.
NewResearch & IP
Work Unit record
Describe one piece of work by its purpose, evidence, authority, risk, handoffs, and accepted outcome.
NewResearch & IP
Workforce Composition map
Assign work across people, AI, rules, software, systems, devices, services, and governance as one operation.
NewResearch & IP
Zero Neo economics
Subscription price is the easiest number to compare and the least decisive. The hypothesis stands or falls on total operating cost, including the costs of assembling badly.
NewResearch & IP
Zero Neo with an IT department
The larger effect may be in organizations that do have IT. Governing a few strategic platforms is a different job from administering hundreds of applications and the integrations between them.
NewResearch & IP
Zero Neo without an IT department
Small businesses historically chose between buying SaaS and hiring consultants. If AI can configure owned platforms, a third option appears for organizations that never had one.
August 2026
NewPortfolio
Digital Native Trials Management System
First filed 2024-12-11. 1 filing on record with the USPTO.
NewResearch & IP
Biotech commercialization should be treated as an engineering discipline
An editorial arguing that biotech commercialization should be run the way engineering is run, with specifications, measurement, and repeatable process, rather than treated as a series of one-off translational events.
NewPortfolio
Biotech commercialization should be treated as an engineering discipline
Published in Journal of Diabetes Science and Technology. DOI 10.1177/19322968261480134.